Bora Biologics, a division of Bora Pharmaceuticals, is a dedicated contract development and manufacturing organisation (CDMO) specialising in biologics, offering integrated solutions across the biologics development lifecycle.

Headquartered in Zhubei, Taiwan, Bora Biologics provides end-to-end support for early-phase biologics development and manufacturing. The division is focused on delivering tailored solutions for complex therapeutic molecules, including monoclonal, bispecific, and multi-specific antibodies, as well as other recombinant proteins. Combining state-of-the-art facilities with technical expertise, Bora Biologics ensures seamless project execution, from discovery through clinical development.

As part of Bora Pharmaceuticals, the biologics division benefits from a robust global infrastructure, including early-stage manufacturing facilities in Taiwan and commercial-scale production and fill-finish capabilities in the United States. Bora Biologics is committed to innovation and quality, enabling its partners to advance their biologics programmes efficiently and reliably.

Key Products and Services

• Discovery Research Support: Lead candidate screening, in vitro assays, and biochemical/physical assays.
• Protein Preparation and Purification: Expertise in monoclonal, bispecific, and multi-specific antibodies, as well as recombinant proteins.
• Process Development: Customised high-yield processes for challenging biologics molecules.
• Early-Phase Manufacturing: Clinical-grade production of complex proteins and antibodies.
• Programme Management: End-to-end support to streamline development workflows.

Bora Biologics continues to position itself as a trusted partner in the biologics space, leveraging its cutting-edge facilities and expert teams to support the development of innovative therapies. With a focus on quality, flexibility, and collaboration, Bora Biologics is dedicated to advancing biologics programmes and improving patient outcomes worldwide.